Lonza, OncoMed to Collaborate on Anti-Cancer Therapeutics

Lonza and OncoMed Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to improving cancer treatment, announced today an agreement for the development and manufacture of OncoMed's pipeline of anti-cancer stem cell therapeutics.

Under the agreement, Lonza will produce material at its mammalian manufacturing facility in Slough, UK. The multi-product GS SystemLicense provides access to Lonza's GS Gene Expression System and Version 8 Media and Feeds Manufacturing Platform.

OncoMed's pipeline is focused on the development of novel monoclonal antibodies that target cancer stem cells.

 

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.